Last Resort Antibiotics Costs and Reimbursement Analysis of Real-Life ICU Patients with Pneumonia Caused by Multidrug-Resistant Gram-Negative Bacteria in Germany.
Julia JeckSebastian M Wingen-HeimannFlorian JakobsJennifer FranzChristoph T BaltinAnna KronBoris BöllMatthias KochanekOliver Andreas CornelyFlorian KronPublished in: Healthcare (Basel, Switzerland) (2022)
Multidrug-resistant Gram-negative bacteria (MDR-GNB) cause serious infections and aggravate disease progression. Last resort antibiotics are effective against MDR-GNB and are reimbursed by flat rates based on German diagnosis-related groups (G-DRG). From a hospital management perspective, this analysis compared hospital reimbursement for last resort antibiotics with their acquisition costs to outline potential funding gaps. Retrospective analyses based on medical charts and real-life reimbursement data included patients with pneumonia due to MDR-GNB treated in intensive care units (ICU) of a German tertiary care hospital (University Hospital Cologne) between January 2017 and December 2020. Drug-associated hospital reimbursement of G-DRG was compared with drug acquisition costs based on preliminarily approved last resort antibiotics (cefiderocol, ceftazidime-avibactam, ceftolozane-tazobactam, and imipenem-cilastatin-relebactam) according to label. Funding gaps were determined for the treatment of Enterobacterales , Pseudomonas aeruginosa , Acinetobacter baumannii , and mixed infections, respectively. Most of the 31 patients were infected with Enterobacterales ( n = 15; 48.4%) and P. aeruginosa ( n = 13; 41.9%). Drug-associated G-DRG reimbursement varied from 44.50 EUR (mixed infection of P. aeruginosa and Enterobacterales ) to 2265.27 EUR ( P. aeruginosa ; mixed infection of P. aeruginosa and Enterobacterales ). Drug acquisition costs ranged from 3284.40 EUR in ceftazidime-avibactam (minimum duration) to 15,827.01 EUR for imipenem-cilastatin-relebactam (maximum duration). Underfunding was found for all MDR-GNB, reaching from 1019.13 EUR ( P. aeruginosa ; mixed infection of P. aeruginosa and Enterobacterales ) to 14,591.24 EUR ( Enterobacterales ). This analysis revealed the underfunding of last resort antibiotics in German hospital treatment. Insufficient reimbursement implies less research in this field, leading to a more frequent use of inappropriate antibiotics. The cycle closes as this contributes to the development of multi-drug resistant bacteria.
Keyphrases
- multidrug resistant
- gram negative
- acinetobacter baumannii
- drug resistant
- klebsiella pneumoniae
- adverse drug
- healthcare
- intensive care unit
- pseudomonas aeruginosa
- acute care
- end stage renal disease
- drug induced
- chronic kidney disease
- machine learning
- single cell
- staphylococcus aureus
- escherichia coli
- respiratory failure
- acute respiratory distress syndrome
- biofilm formation
- deep learning
- climate change
- extracorporeal membrane oxygenation
- replacement therapy
- patient reported